Dysregulation of this process, whether due to mutations in cis-regulatory sequences or alterations in trans-acting splicing factor activity, can have profound effects on the pathogenesis of MASLD. The gene discussed is SLU7; the disease is metabolic dysfunction-associated steatotic liver disease.